Such systemic therapies include traditional chemotherapy for NSCLC, EGFR-TKIs (Gefitinib or Erlotinib), and six kinds of innovative therapies (TMZ, Endostar [Endo], Enzastaurin [Enza], Nitroglycerin [Nitro], and Veliparib [Veli]). Here, EGFR is linked to non-small cell lung carcinoma.